Adaptive Biotechnologies on Monday announced that along with collaborators it will soon present data from more than 30 abstracts about the clinical utility of its next-generation sequencing (NGS)-based clonoSEQ assay in measuring minimal residual disease (MRD) in blood cancer patients.
The abstracts will be presented at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10 to December 13 in New Orleans.
ClonoSEQ is a U.S. Food and Drug Administration (FDA)-cleared assay for MRD assessment in multiple myeloma, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia.
Adaptive recently announced the launch of clonoSEQ to assess MRD in the blood of patients with diffuse large B-cell lymphoma using ctDNA. The assay is widely available to clinicians and patients across the U.S., the firm noted.
MRD testing allows for the direct measurement of the number of cancer cells in the body during and after treatment. Leveraging Adaptive's immune medicine platform, clonoSEQ can detect one cancer cell among a million healthy cells, the firm said.
